Sensitive Detection of DNA Methylation

Authors

  • SUSAN E. COTTRELL,

    Corresponding author
    1. Epigenomics, Inc., Seattle, Washington 98101, USA
      Address for correspondence: Dr. Susan Cottrell, Epigenomics, Inc., 1000 Seneca St., Suite 300, Seattle, WA 98101. Voice: 206-883-2921; fax: 206-254-9151. susan.cottrell@epigenomics.com
    Search for more papers by this author
  • PETER W. LAIRD

    1. Departments of Surgery and of Biochemistry and Molecular Biology, University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California 90089-9176, USA
    Search for more papers by this author

Address for correspondence: Dr. Susan Cottrell, Epigenomics, Inc., 1000 Seneca St., Suite 300, Seattle, WA 98101. Voice: 206-883-2921; fax: 206-254-9151. susan.cottrell@epigenomics.com

Abstract

Abstract: In recent years, many molecular biomarkers have been discovered that are capable of distinguishing tumors from normal tissue. Among the different types of markers, DNA methylation markers stand out for their potential to provide a unique combination of specificity, sensitivity, high information content, and applicability to a wide variety of clinical specimens. Methylation markers are particularly suited for situations where sensitive detection is necessary, such as when tumor DNA is either scarce or diluted by excess normal DNA. One of the most widely used methods for measuring methylation levels, methylation-specific PCR (MSP), has been proved to be a very effective tool in situations requiring sensitive detection. The addition of fluorogenic probes makes these assays more informative, quantitative, and suitable for a clinical format. The field of sensitive detection is not limited to MSP; hence, an alternative methylation-sensitive amplification is discussed. PCR-based methylation assays have been applied to the detection of tumor DNA in a variety of body fluids, including serum, plasma, urine, sputum, and lavage fluids. In many cases, the sensitivity and specificity of these detection assays has been impressive, but important technological issues remain in areas such as sample preparation, assay design, and marker selection. Once these technical concerns have been addressed, the sensitive detection of methylation will provide a powerful diagnostic and prognostic tool, especially for the early detection of preneoplastic and neoplastic lesions.

Ancillary